NT-proBNP in Acute Dyspnea: Effects on Treatment, Hospitalisation and Costs

This study has been completed.
Sponsor:
Information provided by:
Erasmus Medical Center
ClinicalTrials.gov Identifier:
NCT00410293
First received: December 11, 2006
Last updated: NA
Last verified: December 2006
History: No changes posted
  Purpose

Diagnostic uncertainty in patients with complaints of shortness of breath presenting to the Emergency Department of a hospital may delay treatment and proper care. In patients with shortness of breath due to heart failure increased plasma levels of NT-pro-B-type natriuretic peptide (NT-proBNP) can be demonstrated. The use of NT-proBNP as a biomarker for heart failure in patients presenting to the emergency department with dyspnea might improve care and reduce length of hospital stay.

To investigate the effect of NT-proBNP testing on patient care and time to discharge the NT-proBNP test will be randomized. In patients in the study group, the NT-proBNP plasma level is determined at admission and the physician in charge will immediately receive the result of the test. In patients in the control group blood will be sampled but the physician will recieve no information on the NT-proBNP plasma level.

In our study we will investigate the effect of introduction of NT-proBNP as biomarker for heart failure on treatment, time to discharge and costs.


Condition Intervention
Heart Failure
Dyspnea
Procedure: NT-proBNP testing

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Single Blind
Primary Purpose: Diagnostic
Official Title: NT-proBNP Testing in Patients Presenting to the Emergency Department With Acute Dyspnea: Evaluation of Effects on Treatment, Hospitalisation Rate and Costs

Resource links provided by NLM:


Further study details as provided by Erasmus Medical Center:

Primary Outcome Measures:
  • Time to discharge
  • Cost of treatment

Secondary Outcome Measures:
  • Duration of stay at the ED
  • Proportion of patients admitted to the hospital
  • Proportion of patients admitted to an intensive or coronary care unit
  • Specialist consultations
  • Medical treatment
  • Diagnostic investigations

Estimated Enrollment: 500
Study Start Date: December 2004
Estimated Study Completion Date: August 2006
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Age 18 years or older
  • Acute dyspnea as their most prominent complaint

Exclusion Criteria:

  • Acute dyspnea due to a trauma
  • Acute dyspnea due to cardiogenic shock
  • Renal failure requiring dialysis
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00410293

Locations
Netherlands
Erasmus MC
Rotterdam, Netherlands, 3015 CE
Sponsors and Collaborators
Erasmus Medical Center
Investigators
Principal Investigator: Anton H. van den Meiracker, MD, PhD Erasmus MC, Rotterdam, the Netherlands
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00410293     History of Changes
Other Study ID Numbers: MEC-2004-201
Study First Received: December 11, 2006
Last Updated: December 11, 2006
Health Authority: Netherlands: Medical Ethics Review Committee (METC)

Keywords provided by Erasmus Medical Center:
Heart failure
Diagnostic
Natriuretic peptide
NT-pro B-type natriuretic peptide
Length of stay
Costs

Additional relevant MeSH terms:
Dyspnea
Heart Failure
Respiration Disorders
Respiratory Tract Diseases
Signs and Symptoms, Respiratory
Signs and Symptoms
Heart Diseases
Cardiovascular Diseases
Natriuretic Peptide, Brain
Natriuretic Agents
Physiological Effects of Drugs
Pharmacologic Actions
Cardiovascular Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on July 24, 2014